Editorial
The Importance of Glycemic Equipoise in NASH
First published: 26 April 2021
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Alina M. Allen, M.D.
Division of Gastroenterology and Hepatology, Mayo Clinic
200 First Street Southwest
Rochester, MN 55905
E-mail: [email protected]
Tel.: +1-507-284-2511
No abstract is available for this article.
References
- 1Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
- 2Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 2021; 160: 912-918.
- 3Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 2021; 74: 1220–1233.
- 4Nakamura A, Yoneda M, Fujita K, Tajima K, Kikuchi K, Nakajima A, et al. Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. J Diabetes Investig 2011; 2: 483-489.
- 5Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest 2019; 129: 3990-4000.
- 6Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology 2020; 158: 1899-1912.
- 7Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384: 1113-1124.
- 8Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
